Dr. Andrew Blauvelt is a Consultant at Blauvelt Consulting, LLC. He received his undergraduate degree in electrical engineering from Purdue University, his medical degree from Michigan State University, and a Master of Business Administration (MBA) in health care at Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Steve Katz at the National Institutes of Health (NIH). Earlier in his career, he held senior staff positions at the NIH (Senior Investigator), OHSU (Professor), and the Portland Veterans’ Affairs Medical Center (Chief), as well as serving as Owner and President of Oregon Medical Research Center (OMRC) from 2013 to 2022. Within psoriasis immunology research, Dr. Blauvelt’s laboratory published critical papers on the role of IL-23/Th17 biology in this disease. In the clinic, he founded and ran OHSU’s Center of Excellence for Psoriasis and Psoriatic Arthritis, one of the first centers in the country to provide multidisciplinary care for patients with psoriasis. In recent years, while at OMRC, he was the international lead/senior investigator on numerous important clinical trials in psoriasis, including PSTELLAR, FEATURE, CLEAR, IXORA-R, VOYAGE 1, ECLIPSE, IMMhance, BE ABLE 1, BE ABLE 2, BE READY, BE RADIANT, OASIS-1, POETYK PSO-1, and KNOCKOUT. Dr. Blauvelt has published over 450 papers and spoken worldwide on all aspects of psoriasis. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council (IPC), and the International Eczema Council (IEC), and is currently the Chair of the Medical Board for the National Psoriasis Foundation (NPF), an organization he has worked with for over 25 years in various capacities.